Genetics

ARUP Laboratories announced today that the Food and Drug Administration (FDA) has filed ARUP’s premarket approval application (PMA) for an AAV5 total antibody assay.

In collaboration with ARUP Laboratories’ genomic scientists and bioinformatitians, University of Utah Health announced a project with the goal of accurately detecting genetic disorders among newborns.

In a recently published study, Allie Grossmann, MD, PhD, details one factor behind how and why melanoma metastasizes so quickly while identifying better ways to treat this lethal skin cancer.

Recently, three scientists at ARUP published a study that shows how symptoms of CM-AVM can be distinguished from a similar disorder, hereditary hemorrhagic telangiectasia (HHT).

Pharmacogenetics (PGx) is an area of testing that assesses the genes that affect the body’s response to medications.

Kristin Hunt Karner, MD, brings her expertise to ARUP diagnostics every day. She is a medical director for two ARUP departments, Hematopathology and Molecular Oncology.

The laboratorians in the ARUP Immunohematology Reference Laboratory spend their days determining the more complex blood types of patients.

Dr. Gwen McMillin says ARUP's new therapeutic drug monitoring (TDM) for imatinib has definite patient benefits.

HHT affects more than 1.4 million people worldwide. But specialists believe this disorder characterized by abnormal blood vessel development is highly underdiagnosed.

Recreational genetic testing is becoming increasingly popular. Should it matter that physicians or genetic counselors are not part of the equation in how consumers interact with these tests?

For National Kidney Month and Trisomy Awareness Month in March, we have past stories from ARUP Laboratories. Our expert list includes scientists with specialties in renal pathology and genetics.

Pipey is ARUP’s new bioinformatics pipeline and cloud-based computer infrastructure for next generation sequencing (NGS) testing.